Literature DB >> 8703655

Ethnic differences in nifedipine kinetics: comparisons between Nigerians, Caucasians and South Asians.

A Sowunmi1, T J Rashid, O O Akinyinka, A G Renwick.   

Abstract

Nifedipine was administered to 12 healthy Nigerian volunteers as a single oral dose of 20 mg capsule under fasting conditions. The pharmacokinetic results were compared with published data using the same protocol and analytical method for 27 Caucasians and 30 South Asians. The area under the plasma concentration-time curve (AUC) of nifedipine in Nigerians (808 +/- 250 ng ml-1 h) was significantly higher (P < 0.001) than that in Caucasians (323 +/- 116 ng ml-1 h) and the difference remained significant (P < 0.001) when corrected for body weight. The elimination half-life was also significantly higher (P < 0.01) in Nigerians (5.03 +/- 1.96 h) than in Caucasians (2.78 +/- 1.11 h). No significant differences were observed between Nigerians and South Asians in either AUC or half-life of nifedipine. The AUC of the nitropyridine metabolite was higher (P < 0.01) in Nigerians (220 +/- 51 ng ml-1 h) compared with that in Caucasians (154 +/- 56 ng ml-1 h) but the difference was not maintained when corrected for body weight. The AUC corrected for body weight and the elimination half-life of the metabolite were significantly higher in South Asians compared with those of Nigerians and Caucasians. The pharmacokinetics of oral nifedipine in Nigerians were similar to those in South Asians and therefore may also arise from a lower systemic clearance compared with Caucasians as has been reported previously for South Asians.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8703655      PMCID: PMC1365197     

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  34 in total

1.  The trans-hepatic extraction of nifedipine.

Authors:  V F Challenor; D G Waller; A G Renwick; B S Gruchy; C F George
Journal:  Br J Clin Pharmacol       Date:  1987-10       Impact factor: 4.335

2.  Dissociation of co-regulatory control of debrisoquin/phenformin and sparteine oxidation in Ghanaians.

Authors:  N M Woolhouse; M Eichelbaum; N S Oates; J R Idle; R L Smith
Journal:  Clin Pharmacol Ther       Date:  1985-05       Impact factor: 6.875

3.  Residual chloroquine and metabolites in man as a sequel of previous chloroquine medications: a urinary excretion study and its significance.

Authors:  E E Essien; N D Ifudu
Journal:  J Trop Med Hyg       Date:  1984-06

4.  The first pass metabolism of nifedipine in man.

Authors:  D G Waller; A G Renwick; B S Gruchy; C F George
Journal:  Br J Clin Pharmacol       Date:  1984-12       Impact factor: 4.335

5.  Polymorphic acetylation of sulfamethazine in a Nigerian (Yoruba) population.

Authors:  L H Jeyakumar; M R French
Journal:  Xenobiotica       Date:  1981-05       Impact factor: 1.908

6.  Blood quinidine levels and cardiac effects in white British and Nigerian subjects.

Authors:  A Olatunde; D A Price Evans
Journal:  Br J Clin Pharmacol       Date:  1982-10       Impact factor: 4.335

7.  Nifedipine increases and glyceryl trinitrate decreases apparent liver blood flow in normal subjects.

Authors:  J Feely
Journal:  Br J Clin Pharmacol       Date:  1984-01       Impact factor: 4.335

8.  Chromatographic patterns of urinary ethynyl estrogen metabolites in various populations.

Authors:  M C Williams; J W Goldzieher
Journal:  Steroids       Date:  1980-09       Impact factor: 2.668

Review 9.  Genetically determined variability in acetylation and oxidation. Therapeutic implications.

Authors:  D W Clark
Journal:  Drugs       Date:  1985-04       Impact factor: 9.546

10.  Metoprolol and debrisoquin metabolism in Nigerians: lack of evidence for polymorphic oxidation.

Authors:  A O Iyun; M S Lennard; G T Tucker; H F Woods
Journal:  Clin Pharmacol Ther       Date:  1986-10       Impact factor: 6.875

View more
  8 in total

Review 1.  Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans.

Authors:  G R Wilkinson
Journal:  J Pharmacokinet Biopharm       Date:  1996-10

2.  Clinical effects of grapefruit juice-nifedipine interaction in a 54-year-old Nigerian: a case report.

Authors:  Adegboyega Q Adigun; Zainab Mudasiru
Journal:  J Natl Med Assoc       Date:  2002-04       Impact factor: 1.798

3.  Higher Midazolam Clearance in Obese Adolescents Compared with Morbidly Obese Adults.

Authors:  Anne van Rongen; Margreke J E Brill; Janelle D Vaughns; Pyry A J Välitalo; Eric P A van Dongen; Bert van Ramshorst; Jeffrey S Barrett; Johannes N van den Anker; Catherijne A J Knibbe
Journal:  Clin Pharmacokinet       Date:  2018-05       Impact factor: 6.447

4.  Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals.

Authors:  Bregt S Kappelhoff; Alwin D R Huitema; Zeynep Yalvaç; Jan M Prins; Jan W Mulder; Pieter L Meenhorst; Jos H Beijnen
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

5.  Influence of the cytochrome P450 2B6 genotype on population pharmacokinetics of efavirenz in human immunodeficiency virus patients.

Authors:  Salvador E Cabrera; Dolores Santos; María P Valverde; Alfonso Domínguez-Gil; Francisco González; Guillermo Luna; María J García
Journal:  Antimicrob Agents Chemother       Date:  2009-05-11       Impact factor: 5.191

6.  Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals.

Authors:  Monique M R de Maat; Alwin D R Huitema; Jan W Mulder; Pieter L Meenhorst; Eric C M van Gorp; Jos H Beijnen
Journal:  Br J Clin Pharmacol       Date:  2002-10       Impact factor: 4.335

7.  Inter-ethnic comparisons of the pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin.

Authors:  W Mück; S Unger; K Kawano; G Ahr
Journal:  Br J Clin Pharmacol       Date:  1998-06       Impact factor: 4.335

Review 8.  Why do hypertensive patients of African ancestry respond better to calcium blockers and diuretics than to ACE inhibitors and β-adrenergic blockers? A systematic review.

Authors:  Lizzy M Brewster; Yackoob K Seedat
Journal:  BMC Med       Date:  2013-05-30       Impact factor: 8.775

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.